Conversely, injection forms, though being painful and needing help of medical personnel for application, help to quickly achieve necessary concentration of preparation in blood buy antibiotics online Antibiotic is usually chosen in an empiric way (at random). But when choosing one is obligatory guided by definite rules.

Steininger neue tab 25.2.ende

Steininger neue Tab 25.2.ENDE 26.02.2008 15:43 Uhr Seite 1 Therapie der
Influenzavirus -Infektion

Ch. SteiningerAbteilung für Infektiologie und Tropenmedizin, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien Schlüsselwörter:
Zusammenfassung
Key-words:
Einleitung
Steininger neue Tab 25.2.ENDE 26.02.2008 15:43 Uhr Seite 2 Epidemische Influenza
M2-Kanal-Blocker
Tabelle 1: Antivirale Medikamente mit Wirksamkeit gegen Influenzaviren
Substanz-
In vitro-
Antivirale
Indikationen
Nebenwirkungen
Bewertung
mechanis-
Substanz
spektrum
Neuraminidase -Inhibitoren
Steininger neue Tab 25.2.ENDE 26.02.2008 15:43 Uhr Seite 3 Tabelle 2: Dosierung antiviraler Medikamente mit Wirksamkeit gegen Influenzaviren (Österreich)
Antivirale
Handels-
Darreichungs-
Dosierung Erwachsene
Dosierung Kinder
Dosisan-
Applikation
Substanz
Prophylaxe
Therapie
Prophylaxe
Therapie
ab 65 Jahre 1x100 mg ab 65 Jahre 1x100 mg Achtung: möglicherweise ist eine höhere Dosierung im Pandemiefall erforderlich;
ßRimantadin ist nicht mehr verfügbar; *zugelassen ab 5. Lebensjahr; §zugelassen ab 1. Lebensjahr
Pandemische Influenza
1% aller klinischen Isolate resistent.
1% aller klinischen Isolate resistent.
Steininger neue Tab 25.2.ENDE 26.02.2008 15:43 Uhr Seite 4 Antiobstruktive Therapie in der
akuten viralen Erkrankung
Symptomatisch-suppor- kurzzeitige Verbesserungen der kli-
tive und adjuvante
Therapie
Glucocorticoide
Replikations-kompetent in vitro als lässt sich jedoch nicht vorhersagen.
Steininger neue Tab 25.2.ENDE 26.02.2008 15:43 Uhr Seite 5 Vitamine, Echinacea und
Literatur:
Hühnersuppe
T, Hengel H. Low dose oral combinationchemoprophylaxis with oseltamivir and Colopy M, Schweinle J. Clinical signs andsymptoms predicting influenza infection.
amantadine for influenza a virus infections in mice. J Chemother 2007; 19:295-303.
2. Jefferson T, Demicheli V, Di Pietrantonj Govorkova EA. Combination chemothera-py, a potential strategy for reducing the for influenza A in adults. Cochrane Data-base Syst Rev 2006;CD001169.
variants. Antiviral Res 2006; 70:121-31.
Yuen KY. Medical treatment of viral pneu- ly people's technique in using two dry pow- der inhalers to deliver zanamivir: randomis- tent adult. J Infect 2004; 49:262-73.
ed controlled trial. BMJ 2001; 322:577-9.
17. Harrison TW, Oborne J, Newton S, Tat- tersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerba- tions: randomised controlled trial. Lancet 5. Hayden FG, Pavia AT. Antiviral manage- Mink S, Chung K, Lee J. Doubling the dose ment of seasonal and pandemic influenza.
J Infect Dis 2006; 194 Suppl 2:119-126.
T, Medlock J, Leach S. Potential impact of 19. Patel H, Platt R, Lozano JM, Wang EE.
antiviral drug use during influenza pande- Glucocorticoids for acute viral bronchioli- mic. Emerg Infect Dis 2005; 11:1355-62.
tis in infants and young children. Cochrane mez S, et al. Strategies for containing an 8. Longini IM, Jr., Nizam A, Xu S, et al.
wheezing associated with viral infection in 9. Jefferson TO, Demicheli V, Di Pietran-tonj C, Jones M, Rivetti D. Neuraminidase inhibitors for preventing and treating influ- steroids for episodic viral wheeze of child- enza in healthy adults. Cochrane Database hood. Cochrane Database Syst Rev 2000;CD001107.
10. Ward P, Small I, Smith J, Suter P, Dut-kowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influen- 11. Le QM, Kiso M, Someya K, et al. Avian chiolitis. Pediatrics 2006; 118:1774-93.
flu: isolation of drug-resistant H5N1 virus.
24. Singh M. Heated, humidified air for the 12. Mishin VP, Hayden FG, Gubareva LV.
Susceptibilities of antiviral-resistant influ- 25. Van Straten M, Josling P. Preventing the enza viruses to novel neuraminidase inhi- et al. Resistant influenza A viruses in child- min A for treating measles in children.
ren treated with oseltamivir: descriptive Steininger neue Tab 25.2.ENDE 26.02.2008 15:43 Uhr Seite 6 27. Ni J, Wei J, Wu T. Vitamin A for non-measles pneumonia in children. CochraneDatabase Syst Rev 2005;CD003700.
28. Turner RB, Bauer R, Woelkart K, Hul-sey TC, Gangemi JD. An evaluation ofEchinacea angustifolia in experimental rhi-novirus infections. N Engl J Med 2005;353:341-8.
29. Marshall I. Zinc for the common cold.
Cochrane Database Syst Rev 2000;CD001364.
Anschrift des Verfassers:
Dr. Christoph SteiningerUniv.-Klinik für Innere Medizin I, Klin.
Abt. für Infektionen und Tropenmedizin A-1090 Wien, Währinger Gürtel 18-20 E-Mail:[email protected]

Source: http://www.infektionsnetz.de/test/aktuelles/Steininger_Influenzavirusinfektion.pdf

Microsoft word - visits to other churches.doc

Visits to other Churches 16 parishioners and parish architect Peter Ferguson, led by Fr. Dermot and William McAuliffe, went to see four other Dublin parishes on Saturday, January 23rd 2010. The purpose of the tour was to see how other parishes had adapted their church building to the current realities and needs of their community. In Edenmore, Raheny , the front portion of their church build

Renitec, inn-enalapril

RESUMO DAS CARACTERÍSTICAS DO MEDICAMENTO NOTA: ESTE RCM FOI O ANEXADO Á DECISÃO DA COMISSÃO, RELATIVA Á SUBMISSÃO PARA ARBITRAGEM; O TEXTO VÁLIDO NA ALTURA. O TEXTO NÃO É REVISTO OU ACTUALIZADO PELA EMEA E POR ISSO NÃO REPRESENTA NECESSARIAMENTE O TEXTO ACTUAL. 1. DENOMINAÇÃO MEDICAMENTO < Renitec e denominações associadas (ver Anexo I)>, <dosagem>,

Copyright © 2010-2014 Medical Articles